285 related articles for article (PubMed ID: 33491253)
1. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity.
Hamzic S; Schärer D; Offer SM; Meulendijks D; Nakas C; Diasio RB; Fontana S; Wehrli M; Schürch S; Amstutz U; Largiadèr CR
Br J Clin Pharmacol; 2021 Aug; 87(8):3234-3243. PubMed ID: 33491253
[TBL] [Abstract][Full Text] [Related]
2. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.
Medwid S; Wigle TJ; Kim RB
Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798
[TBL] [Abstract][Full Text] [Related]
3. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Božina N; Bilić I; Ganoci L; Šimičević L; Pleština S; Lešnjaković L; Trkulja V
Br J Clin Pharmacol; 2022 May; 88(5):2190-2202. PubMed ID: 34780066
[TBL] [Abstract][Full Text] [Related]
4. Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study.
Miarons M; Manzaneque Gordón A; Riera P; Gutiérrez Nicolás F;
Oncologist; 2023 May; 28(5):e304-e308. PubMed ID: 37014829
[TBL] [Abstract][Full Text] [Related]
5. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
6. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
[TBL] [Abstract][Full Text] [Related]
8. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
Froehlich TK; Amstutz U; Aebi S; Joerger M; Largiadèr CR
Int J Cancer; 2015 Feb; 136(3):730-9. PubMed ID: 24923815
[TBL] [Abstract][Full Text] [Related]
9. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
[TBL] [Abstract][Full Text] [Related]
10. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
[TBL] [Abstract][Full Text] [Related]
11. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
[TBL] [Abstract][Full Text] [Related]
12. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Del Re M; Cinieri S; Michelucci A; Salvadori S; Loupakis F; Schirripa M; Cremolini C; Crucitta S; Barbara C; Di Leo A; Latiano TP; Pietrantonio F; Di Donato S; Simi P; Passardi A; De Braud F; Altavilla G; Zamagni C; Bordonaro R; Butera A; Maiello E; Pinto C; Falcone A; Mazzotti V; Morganti R; Danesi R
Pharmacogenomics J; 2019 Dec; 19(6):556-563. PubMed ID: 30723313
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
Hamzic S; Aebi S; Joerger M; Montemurro M; Ansari M; Amstutz U; Largiadèr C
Swiss Med Wkly; 2020 Nov; 150():w20375. PubMed ID: 33232506
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.
Gentile G; Botticelli A; Lionetto L; Mazzuca F; Simmaco M; Marchetti P; Borro M
Pharmacogenomics J; 2016 Aug; 16(4):320-5. PubMed ID: 26216193
[TBL] [Abstract][Full Text] [Related]
16. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Menghi M; Magnani M
Br J Cancer; 2017 Oct; 117(9):1269-1277. PubMed ID: 29065426
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Amstutz U; Farese S; Aebi S; Largiadèr CR
Pharmacogenomics; 2009 Jun; 10(6):931-44. PubMed ID: 19530960
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
Pallet N; Hamdane S; Garinet S; Blons H; Zaanan A; Paillaud E; Taieb J; Laprevote O; Loriot MA; Narjoz C
Br J Cancer; 2020 Sep; 123(5):811-818. PubMed ID: 32595208
[TBL] [Abstract][Full Text] [Related]
19. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
20. Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients.
Riera P; Riba M; Bernal S; Virgili AC; Páez D; Moreno ME
Farm Hosp; 2021 Dec; 45(7):5-10. PubMed ID: 35379107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
